Using risperidone for Alzheimer's dementia-associated psychosis

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 14, 2008, Pages 2537-2543

  McNeal, Karleen M ^a   Meyer, Renee P ^a   Lukacs, Karen ^a   Senseney, Anna ^a   Mintzer, Jacob ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alzheimer's disease; Atypical antipsychotics; Dementia; Elderly; Risperidone

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PHYSOSTIGMINE; PLACEBO; QUETIAPINE; RISPERDAL M TAB; RISPERIDONE; UNCLASSIFIED DRUG;

AGGRESSION; AGING; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOPAMINE RECEPTOR BLOCKING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ELDERLY CARE; EXTRAPYRAMIDAL SYMPTOM; FALLING; HUMAN; LOW DRUG DOSE; MUSCLE STIFFNESS; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PREVALENCE; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 54349118426     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.14.2537     Document Type: Review

References (52)

1. Hansberry MR, Chen E, Gorbien MJ. Dementia and elder abuse. Clin Geriatr Med 2005;21:315-32
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-22
3. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997;278:1363-71
4. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8:29-34
5. White KE, Cummings JL. Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies. Compr Psychiatry 1996;37(3):188-95
6. Tran M, Bedard M, Molloy DW, et al. Associations between psychotic symptoms and dependence in activities of daily living among older adults with Alzheimer's disease. Int Psychogeriatr 2003;15:171-9
7. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54:1965-71
8. Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry 2001;16:1156-62
9. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-55
10. Tariot PN. The older patient: the ongoing challenge of efficacy and tolerability. J Clin Psychiatry 1999;60(Suppl 23):29-33
11. Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry 2000;61(Suppl 8):43-9; discussion 50-1
12. Pharmaceuticals OM-J. Risperdal: full US prescribing information; 2008
13. Mintzer JE. Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. J Clin Psychiatry 2001;62(Suppl 21):23-5
14. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioral disturbance in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-34
15. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001;18:45-61
16. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-15
17. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989;46:587-99
18. Mintzer J, Brawman-Mintzer O, Mirski DF, et al. Fenfluramine challenge test as a marker of serotonin activity in patients with Alzheimer's dementia and agitation. Biol Psychiatry 1998;44:918-21
19. Love RC, Nelson MW. Pharmacology an clinical experience with risperidone. Expert Opin Pharmacother 2000;1:1441-53
20. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003;64:134-43
21. Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004;12:509-16
22. Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry 2006;14:280-91
23. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38
24. Cooper JW. Adverse drug reaction-related hospitalizations of nursing facility patients: a 4-year study. South Med J 1999;92:485-90
25. Madhusoodanan S, Suresh P, Brenner R, Pillai R. Experience with the atypical antipsychotics - risperidone and olanzapine in the elderly. Ann Clin Psychiatry 1999;11:113-8
26. Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-7
27. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. Int J Geriatr Psychiatry 2000;15:506-14
28. Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999;19:57-61
29. Advisory FPH. United States Food and Drug Administration. Deaths with antipsychotics in elderly patients with behavioral disturbances; 2005
30. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43
31. Atypical antipsychotics in the elderly. Med Lett Drugs Ther 2005;47:61-2
32. Aupperle P. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimers Dis Other Demen 2006;21:101-8
33. Baker W. Relative frequencies of Alzheimer disease, lewy body, vascular and frontotemporal dementia, hippocampal sclerosis in the state of Florida brain bank. Alzheimer Dis Assoc Disord 2002;16:203-12
34. Barrett J. Knowledge about Alzheimer's disease among primary care physicians, psychologists, nurses and social workers. Alzheimer Dis Acsoc Disord 1997;2:99-106
35. Conley, RR. Risperidone side effects. J Clin Psychiatry 2000;61(Suppl 8):20-3
36. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 1998;155:1512-9
37. Doraiswamy P. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol 2002;57:173-7
38. Goldberg RJ, Goldberg J. Risperidone for dementia related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-8
39. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-5
40. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 2000;1:783-801
41. Laughren T. A regulatory perspective on psychiatric syndromes in Alzheimer's disease. Am Assoc Geriatr Psychiatry 2001;9:340-5
42. Mintzer J. What are the challenges faced by psychiatrists in the management of Alzheimer's disease? CNS Spectr 2004;9:13-5
43. Mittelman M. A family intervention to delay nursing home placement of patients with Alzheimer disease. JAMA 1996;276:1725-8
44. Palmer AM, Stratmann GC, Proctor AW, Bowen DM. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988;23:616-20
45. Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriat 1996;8:301-8
46. Suh GH, Son HG, Ju YS, et al. A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004;12:509-16
47. Wadley V. Diagnostic attributions versus labeling: impact of Alzheimer's disease and major depression diagnoses on emotions, beliefs and helping intentions of family members. J Gerontol 2001;56:244-52
48. Zaleon CR, Guthrie SK. Antipsychotic drug use in older adults. Am J Hosp Pharm 1994;51:17-43
49. Schneider LS, Katz IR, Park S, et al. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry 2003;11:414-25
50. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer's disease. Arch Neurol 1994;51:676-81
51. Feil N. The validation breakthrough: simple techniques for communication with people with Alzheimer's-type dementia. Baltimore: Health Professions Press; 1991
52. Clark L. Interventions for persons with Alzheimer's disease: strategies for maintaining and enhancing communicative success. Top Lang 1995;15:47-65